Trifecta Capital Advisors LLC Grows Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Trifecta Capital Advisors LLC lifted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,538 shares of the pharmaceutical company’s stock after purchasing an additional 573 shares during the quarter. Vertex Pharmaceuticals comprises approximately 1.5% of Trifecta Capital Advisors LLC’s holdings, making the stock its 20th largest position. Trifecta Capital Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $7,048,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Norges Bank purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $1,374,948,000. GAMMA Investing LLC lifted its position in Vertex Pharmaceuticals by 60,572.3% in the 1st quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company’s stock valued at $1,175,722,000 after acquiring an additional 2,421,073 shares in the last quarter. Parnassus Investments LLC purchased a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $731,283,000. Capital World Investors increased its holdings in shares of Vertex Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock worth $11,406,667,000 after purchasing an additional 1,514,993 shares in the last quarter. Finally, Capital Research Global Investors raised its stake in shares of Vertex Pharmaceuticals by 15.8% in the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock worth $4,199,713,000 after purchasing an additional 1,426,746 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on VRTX shares. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Leerink Partners reiterated a “market perform” rating and issued a $503.00 price target (down from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. JPMorgan Chase & Co. increased their price objective on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an “overweight” rating in a research report on Tuesday, May 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $535.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Finally, Royal Bank Of Canada set a $420.00 target price on shares of Vertex Pharmaceuticals and gave the company a “sector perform” rating in a research note on Tuesday. Fourteen equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $513.32.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $448.40 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. The company’s fifty day moving average price is $460.63 and its 200-day moving average price is $459.78. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a market capitalization of $115.15 billion, a PE ratio of -114.39 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.76 EPS. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.